

SAFETY DATA SHEET



1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material	AUGMENTIN TABLETS
Synonym(s)	AUGMENTIN 156.25 MG TABLETS * AUGMENTIN 250 MG TABLETS * AUGMENTIN 500 MG TABLETS * AUGMENTIN 187.5 MG TABLETS * AUGMENTIN 375 MG TABLETS * AUGMENTIN 625 MG TABLETS * AUGMENTAN TABLETS * AUGMENTIN 2:1 TABLETS * AUGMENTIN 4:1 TABLETS * CLAVULIN 250 TABLETS * CLAVULIN 500F TABLETS * AMOCLAV 375 MG TABLETS * AMOCLAV 625 MG TABLETS * CLAMOXYL TABLETS 250 MG * SPEKTRAMOX 375 MG FINAL TABLETS * NDC NO. 0029-6075-27 * NDC NO. 0029-6075-31 * NDC NO. 0029-6080-12 * NDC NO. 0029-6080-31 * AMOXICILLIN TRIHYDRATE AND POTASSIUM CLAVULANATE, FORMULATED PRODUCT
Company Name	<p>GlaxoSmithKline, Corporate Environment, Health & Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK</p> <p>UK General Information: +44-20-8047-5000 Transport Emergency (EU) +44-1865-407333 Medical Emergency +1-612-221-3999, Ext 221 Information and Advice: US number, available 24 hours Multi-language response</p> <p>GlaxoSmithKline, Corporate Environment, Health & Safety One Franklin Plaza, 200 N 16th Street Philadelphia, PA 19102-1225 US</p> <p>US General Information: +1-888-825-5249 Transport Emergency (non EU) +1-703-527-3887 US number, available 24 hours Multi-language response</p>

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
AMOXICILLIN TRIHYDRATE	61336-70-7	35 to 60	
NON-HAZARDOUS INGREDIENTS	Unassigned	16 to 59	
POTASSIUM CLAVULANATE	61177-45-5	6 to 24	262-640-9

3. HAZARDS IDENTIFICATION

Fire and Explosion	Expected to be non-combustible.
Health	<p>Exposure might occur via skin; eyes; ingestion. May produce allergic skin reactions. Respiratory allergen. Possible effects of overexposure in the workplace include: symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing); nausea; vomiting; diarrhoea. Health effects information is based on hazards of components.</p>

Material AUGMENTIN TABLETS

Environment No information is available about the potential of this product to produce adverse environmental effects.

4. FIRST-AID MEASURES

Ingestion Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.

Inhalation Physical form suggests that risk of inhalation exposure is negligible.

Skin Contact Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.

Eye Contact Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre. Medical treatment in cases of overexposure should be treated as an overdose of penicillin antibiotic. In allergic individuals, exposure to this material may require treatment for initial or delayed allergic symptoms and signs. This may include immediate and/or delayed treatment of anaphylactic reactions.

Medical Conditions Caused or Aggravated by Exposure Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product. Ocular symptoms may be indicative of allergic reaction. Pulmonary symptoms may indicate allergic reaction or asthma. This material may cause or aggravate allergy to penicillin antibiotics.

Antidotes No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards Not expected for the product, although the packaging is combustible.

Extinguishing Media Water, dry powder or foam extinguishers are recommended. Carbon dioxide extinguishers may be ineffective.

Special Firefighting Procedures For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.

Hazardous Combustion Products Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods Collect and place it in a suitable, properly labelled container for recovery or disposal.

Decontamination Procedures No specific decontamination or detoxification procedures have been identified for this product. Water can be used for clean-up and decontamination operations.

7. HANDLING AND STORAGE

HANDLING

General Requirements Avoid breaking or crushing tablets.

STORAGE

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

INGREDIENT	AMOXICILLIN TRIHYDRATE	
GSK Occupational Hazard Category	3	
GSK Occupational Exposure Limit	100 MCG/M3 (15 MIN STEL)	RESPIRATORY SENSITISER, SKIN SENSITISER
INGREDIENT	POTASSIUM CLAVULANATE	
GSK Occupational Hazard Category	1	
GSK Occupational Exposure Limit	5000 MCG/M3 (8 HR TWA)	
Occupational Hygiene Air Monitoring Methods	For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional.	
ENGINEERING CONTROLS		
Exposure Controls	An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Refer to the Exposure Control Matrix for more information about how ECA's are assigned and how to interpret them.	
PERSONAL PROTECTIVE EQUIPMENT		
Eye Protection	Wear approved safety glasses with side shields if eye contact is possible.	
Respirators	If respiratory protective equipment (RPE) is used, the type of RPE will depend upon air concentrations present, required protection factor as well as hazards, physical properties and warning properties of substances present.	
Other Equipment or Procedures	Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.	

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	
Colour	White.
Physical Form	Film-coated tablet.

10. STABILITY AND REACTIVITY

Stability	This product is expected to be stable.
Conditions to Avoid	None for normal handling of this product.

11. TOXICOLOGY INFORMATION

Pharmacological Effects	This material is a penicillin; an antibiotic.
Target Organ Effects	No specific target organ effects have been identified.
Routes of Exposure	
Oral Toxicity	Not expected to be toxic following ingestion.
Inhalation Toxicity	Adverse effects might occur following inhalation.
Skin Effects	Irritation might occur following direct contact.
Eye Effects	Minor irritation might occur following direct contact with eyes.
Sensitisation	Allergic skin reactions might occur following dermal exposure. Assessment based upon effects of structurally similar substances.
Genetic Toxicity	Not expected to be genotoxic under occupational exposure conditions. Assessment based upon effects of structurally similar substances.
Carcinogenicity	Not expected to produce cancer in humans under occupational exposure conditions. No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.

Material AUGMENTIN TABLETS

Reproductive Effects Not expected to produce adverse effects on fertility or development under occupational exposure conditions. No adverse effects have been reported following extensive use or exposure in humans.

12. ECOLOGICAL INFORMATION

Summary This material contains two or more active pharmaceutical ingredients that have been tested, one of which may be harmful if released directly to the environment. Specific information on that active pharmaceutical ingredient is provided below. Consult the MSDS of the active ingredient for specific information about potential environmental effects. Appropriate precautions should be taken to limit release of this material to the environment. Local regulations and procedures should be consulted prior to environmental release.

ECOTOXICITY**Aquatic****Algal**

This material contains an active pharmaceutical ingredient that is harmful to algae.

IC50: 56 mg/L, 72 Hours, Selenastrum capricornutum, green algae

NOEC: 9.4 mg/L, 72 Hours, Selenastrum capricornutum, green algae

Daphnid

This material contains an active pharmaceutical ingredient that is not toxic to daphnids.

EC50: 1610 mg/L, 48 Hours, Daphnia magna, Static test

NOEC: 530 mg/L, 48 Hours, Daphnia magna, Static test

Fish

This material contains an active pharmaceutical ingredient that is not toxic to fish.

Adult Lepomis macrochirus, bluegill sunfish

EC50: > 790 mg/L, 96 Hours, Static test

Adult Lepomis macrochirus, bluegill sunfish

NOEC: 790 mg/L, 96 Hours, Static test

Adult Oncorhynchus mykiss, rainbow trout

EC50: > 960 mg/L, 96 Hours, Static test

Adult Oncorhynchus mykiss, rainbow trout

NOEC: 960 mg/L, 96 Hours, Static test

MOBILITY**Solubility**

This material contains an active pharmaceutical ingredient that for environmental fate predictions has solubility in water.

Partitioning

This material contains an active pharmaceutical ingredient with octanol/water partition coefficient data that suggests that for environmental fate predictions the active pharmaceutical ingredient will not have the tendency to distribute into fats.

PERSISTENCE/DEGRADATION**Hydrolysis**

This material contains an active pharmaceutical ingredient that has been shown to be chemically unstable in water. Hydrolysis may be a significant depletion mechanism.

Half-Life, Neutral: 28.3 Hours, Measured

Half-Life, Acidic: 11.9 Hours, Measured

Half-Life, Basic: 9.92 Hours, Measured

Biodegradation

This material contains an active pharmaceutical ingredient that is not readily biodegradable but is inherently biodegradable (as defined by 1993 OECD Testing Guidelines) and is not expected to persist in the environment.

Aerobic - Inherent

Percent Degradation: 90 %, 28 days, Zahn-Wellens, Activated sludge

Bioaccumulation

This material contains an active pharmaceutical ingredient that will not have a tendency to bioaccumulate in the food chain.

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations	Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.
Regulatory Requirements	Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information	Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.
------------------------------	---

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)

Classification	This dosage form is exempt from the requirements of the OSHA Hazard Communication Standard.
-----------------------	---

Other US Regulations

TSCA Status	Exempt
--------------------	--------

16. OTHER INFORMATION

References	GSK Hazard Determination
-------------------	--------------------------

SDS Version Number	19
---------------------------	----

SDS Sections Updated

Sections	Subsections
COMPOSITION / INFORMATION ON INGREDIENTS	

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.